Growing placebo response rate: The problem in recent therapeutic trials?

Psychopharmacology Bulletin

Volumn 33, Issue 1, 1997, Pages 31-39

  Uhlenhuth, E H ^a,c   Matuzas, William ^b   Warner, Teddy D ^a   Thompson, Peter M ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

baseline pathology; clinical trials; panic disorder; placebo response; regression analysis

Indexed keywords

ALPRAZOLAM; IMIPRAMINE; PLACEBO;

AGORAPHOBIA; ANXIETY NEUROSIS; ARTICLE; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG RESEARCH; HUMAN; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PANIC; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ALPRAZOLAM; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CLINICAL TRIALS; DOUBLE-BLIND METHOD; HUMANS; IMIPRAMINE; PANIC DISORDER; PLACEBO EFFECT; RESEARCH DESIGN;

EID: 0030897097     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Aronson, TA. A naturalistic study of imipramine in panic disorder and agoraphobia. Am. J. Psychiatry 144:1014-1019, 1987.
2. Ballenger, JC; Burrows, GD; DuPont, RL; Lesser, IM; Noyes, R Jr; Pecknold, JC; Rifkin, A; and Swinson, RP. Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial. I. Efficacy in short-term treatment. Arch. Gen. Psychiatry 45:413-422, 1988.
3. Ballenger, JC; Peterson, GA; Laraia, M; Hucek, A; Lake, CR; Jimerson, D; Cox, DJ; Trockman, C; Shipe, JR Jr, and Wilkinson, G. A study of plasma catecholamines in agoraphobia and the relationship of serum tricyclic levels to treatment response. In: Ballenger, JC, ed. Biology of Agoraphobia, Washington, DC: American Psychiatric Press, 1984.
4. Barlow, DH. Anxiety and Its Disorders. New York: Guilford Press, 1988.
5. Beck, AT, and Emery, G. Anxiety Disorders and Phobias: A Cognitive Perspective. New York: Basic Books, 1985.
6. Benjamin, LS. Statistical treatment of the Law of Initial Values (LIV) in autonomic research: A review and recommendation. Psychosom. Med. 25:556-566, 1963.
7. Cross-National Collaborative Panic Study, Second Phase Investigators. Drug treatment of panic disorder Comparative efficacy of alprazolam, imipramine, and placebo. Br. J. Psychiatry 160:191-202, 1992.
8. Elkin, I; Shea, MT; Watkins, JT; Imber, SD; Sotsky, SM; Collins, JF; Glass, DR; Pilkonis, PA; Leber, WR; Docherty, JP; Fiester, SJ; and Parloff, MB. National Institute of Mental Health Treatment of Depression Collaborative Research Program: General effectiveness of treatments. Arch. Gen. Psychiatry 46:971-982, 1989.
9. Fisher, S; Lipman, RS; Uhlenhuth, EH; Rickels, K; and Park, LC. Drug effects and initial severity of symptomatology. Psychopharmacologia 7:57-60, 1965.
10. Gelder, MG. Panic attacks: New approaches to an old problem. Br. J. Psychiatry 149:346-352, 1986.
11. Greenblatt, DJ; Harmatz, JS; and Shader, RI. Plasma alprazolam concentrations: Relation to efficacy and side effects in the treatment of panic disorder. Arch. Gen. Psychiatry 50:715-722, 1993.
12. Hirschfeld, RMA; Kane, J; and Schatzberg, A. "Determinants of Placebo Response Rates in Clinical Trials." Symposium presented at the 35th Annual Meeting of the New Clinical Drug Evaluation Unit Program, Orlando, FL, June 2, 1995.
13. Howell, PC. Statistical Methods for Psychology, 3rd ed. Boston: PWS-Kent, 1992.
14. Huitema, BE. The Analysis of Covariance and Alternatives. New York: Wiley, 1980.
15. Hunka, S. Identifying the regions of significance in ANCOVA problems having non-homogeneous regressions. Br. J. Math Stat. Psychol. 48:161-188, 1995.
16. Klein, DF. Anxiety reconceptualized. Compr. Psychiatry 21:411-427, 1980.
17. Klein, DF, and Fink, M. Psychiatric reaction patterns to imipramine. Am. J. Psychiatry 119:432-438, 1962.
18. Klein, DF, and Ross, DC. Reanalysis of the National Institute of Mental Health Treatment of Depression Collaborative Research Program General Effectiveness Report. Neuropsychopharmacology 8:241-251, 1993.
19. Klein, DF; Ross, DC; and Cohen, P. Panic and avoidance in agoraphobia: Application of path analysis to treatment studies. Arch. Gen. Psychiatry 44:377-385, 1987.
20. Lipman, RS; Park, LC; and Rickels, K. Paradoxical influence of a therapeutic side-effect interpretation. Arch. Gen. Psychiatry 15:462-474, 1966.
21. Marks, IM. Fears and Phobias. London: William Heinemann Medical Books Ltd, 1969.
22. Marks, IM; Gray, S; Cohen, D; Hill, R; Mawson, D; Ramm, E; and Stern, RS. Imipramine and brief therapist-aided exposure in agoraphobics having self-exposure homework. Arch. Gen. Psychiatry 40:153-162, 1983.
23. Mavissakalian, MR, and Perel, JM. Dose-response characterization of anti-panic effect of imipramine. Psychopharmacol. Bull. 30:171-174, 1994.
24. Mavissakalian, MR, and Perel, JM. Imipramine treatment of panic disorder with agoraphobia: Dose ranging and plasma level-response relationships. Am. J. Psychiatry 152:673-682, 1995.
25. Pohl, R; Yerevgani, VK; Balon, R; and Lycaki, H. The jitteriness syndrome in panic disorder patients treated with antidepressants. J. Clin. Psychiatry 49:100-104, 1988.
26. Potthoff, RF. On the Johnson-Neyman Technique and some extensions thereof. Psychometrika 29:241-256, 1964.
27. Rapee, RM. Psychological factors in panic disorder. Special Issue: Panic, cognitions, and sensations. Adv. Behav. Res. Ther. 15:85-102, 1993.
28. Rickels, K, and Schweizer, E. "Are Drug-Placebo Differences in the Treatment of Anxiety Disorders Shrinking Over the Years?" Presented at the XXth Congress of the Collegium Internationale Neuropsychopharmacologicum, Melbourne, Australia, June 23-27, 1996.
29. Rogosa, D. Comparing non-parallel regression lines. Psychol. Bull. 88:307-321, 1980.
30. Rogosa, D. On the relationship between the Johnson-Neyman region of significance and statistical tests of parallel within-group regressions. Educ. Psychol. Meas. 41:73-84, 1981.
31. Schweizer, E; Patterson, W; Rickels, K; and Rosenthal, M. Double-blind, placebo-controlled study of once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder. Am. J. Psychiatry 150:1210-1215, 1993.
32. Sheehan, DV; Ballenger, J; and Jacobsen, G. Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch. Gen. Psychiatry 37:51-59, 1980.
33. Uhlenhuth, EH; Lipman, RS; Rickels, K; Fisher, S; Covi, L; and Park, LC. Predicting the relief of anxiety with meprobamate. Arch. Gen. Psychiatry 19:619-630, 1968.
34. Uhlenhuth, EH; Matuzas, W; Glass, RM; and Easton, C. Response of panic disorder to fixed doses of alprazolam or imipramine. J. Affect. Disord. 17:261-270, 1989.
35. Wilcox, RR. Pairwise comparisons of J independent regression lines over a finite interval, simultaneous pairwise comparison of their parameters, and the Johnson-Neyman procedure. Br. J. Math Stat. Psychol. 40:80-93, 1987.
36. Wilder, J. Modern psychophysiology and the Law of Initial Value. Am. J. Psychother. 12:199-221, 1958.
37. Wilder, J. Basimetric Approach to Psychiatry. In: Arieti, S, ed. American Handbook of Psychiatry, Vol. 3. New York: Basic Books, 1966. pp. 333-343.
38. Wolpe, J, and Rowan, VC. Panic disorder: A product of classical conditioning. Behav. Res. Ther. 26:441-450, 1988.